Big pharma puts bets on alpha-synuclein in Parkinson’s – but will they pay off?

[Farooqji]

Several pharma companies think that targeting a rogue protein known as alpha-synuclein could be the key to halting or reversing neurodegeneration in Parkinson’s disease – but has the industry learned from a string of failures in Alzheimer’s? In the space of a few weeks, Novartis AG and Sanofi AS have signed major deals for molecules targeting misfolded alpha-synuclein, the rogue protein thought to be the root cause of Parkinson’s disease

bioworld.com/articles/51555...

[kaypeeoh]

Is there any evidence that alpha-synuclein is the culprit rather than an innocent side effect?

[jeffreyn in reply to kaypeeoh]

There is clear evidence that alpha-synuclein plays a part.

The full extent of that part is not yet clear.